盐酸恩诺沙星
|
|
|
- CAS号:
- 93106-59-3
- 英文名:
- ENROFLOXAIN HYDROCHLORIDE
- 英文别名:
- ENROFLOXAIN HYDROCHLORIDE;3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
- 中文名:
- 盐酸恩诺沙星
- 中文别名:
- 恩诺沙星单盐酸盐
- CBNumber:
- CB91504238
- 分子式:
- C19H23ClFN3O3
- 分子量:
- 395.8556232
- MOL File:
- 93106-59-3.mol
|
|
|
盐酸恩诺沙星化学性质
-
储存条件:
-
Store at -20°C
-
|
-
水溶解性:
-
Water : 7.14 mg/mL (Need ultrasonic)
-
|
盐酸恩诺沙星性质、用途与生产工艺
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) 是一种有效的抗生素，作用于 Mycoplasma bovis，MIC90 为 0.312 μg/ mL。
MIC90: 0.312 μg/mL (
Mycoplasma bovis
)
Mycoplasma bovis
is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL.
Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment.
盐酸恩诺沙星
上下游产品信息
上游原料
下游产品
93106-59-3, 盐酸恩诺沙星 相关搜索:
- Pharmacutical raw materials
- 医药原料
- 兽药原料
- 恩诺沙星单盐酸盐
- 93106-59-3
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
- ENROFLOXAIN HYDROCHLORIDE